Fig. 5.

Pathway analysis and therapeutic intervention. a Clinical sample analysis. Harvested cells are first differentiated into host and cancer cells and subsequent analyses are performed on the latter. Primary drug targets are shown in green. b Image analysis of ~500 T47D cells before/after exposure to targeted therapeutics showing initial response normalized to 1 and their measured, corrected fluorescence response according to the described scale bar. c Dose–response analysis of alpelisib (BYL-719), a selective PI3K inhibitor of p110α. The violin plots show sample heterogeneity to response and are consistent with an IC50 of <1 μM in the T47D cell line